Antinuclear Antibody Test Market

Antinuclear Antibody Test Market by Products (Reagents & Assay Kits, Systems, and Software & Services), Techniques (ELISA, Immunofluorescence Assay, and Multiplex Assay), Applications (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s Syndrome, Scleroderma, and Others), End-users (Hospitals, Clinical Laboratories, Physician Office Laboratories, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-810
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 186
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global antinuclear antibody test market size is projected to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the high occurrence of autoimmune disorders along with increasing awareness of these diseases.
 

Antinuclear Antibody Test Market Key Takeaways


Antinuclear antibody (ANA) tests, also known as fluorescent antinuclear antibody tests, are blood tests that locates certain antibodies present in the host. Antibodies are various proteins found in the immune system of the host to ward off viruses, bacteria, and other germs. However, there are times when the immune system categorize the parts of the host’s body as foreign invaders and releases antibodies to harm the host. ANA tests are conducted to identify these mistakes taking place in the host’s body and rectify this situation.

The American Autoimmune Related Disease Association (AARDA) conducted a survey, which reported that over 50 million people suffered from autoimmune disorders and diseases in the US. The occurrence of these kinds of diseases is increasing every year, not only in the US, but also across the world. According to the AARDA, women also accounted for 80% of all patients suffering from autoimmune diseases and was one of the major diseases responsible for several death of women. One common method to diagnose this disease is done by using the antinuclear antibody testing. The ANA is currently used as an important tool for the diagnosis and management of autoimmune diseases and illness such as rheumatoid arthritis and systemic lupus erythematosus or the SLE, monitored at both primary care and sub-specialty settings.

The COVID-19 pandemic has reduced the growth of the global antinuclear antibody test market initially. However, upon further studies, researchers and scientists found out that the coronavirus has the viral gene of accelerating illness of the hosts. This steered to hospitals, clinics, and healthcare laboratories to focus more on the treatment of autoimmune disorders for the prevention and treatment of diseases and this led to its market growth.

Market Trends, Drivers, Restraints, and Opportunities

  • The major driver for the global antinuclear antibody test market is the increasing demand of antinuclear antibody testing, particularly in the interests of primary care physicians at hospitals and other healthcare delivery systems.
  • The increase in funding and investments from both the government and private investors to the diagnosis to autoimmune disorders has become a huge driver for the growth in this market.
  • In the recent ANA testing, there has been multiple concerns regarding the procedure and results due to lack of accuracy. This can be a key restraining factor for the global antinuclear antibody test market size.
  • High cost in performing of the ANA diagnosis and lack of advanced healthcare facilities especially in developing regions present a major restraint in the global antinuclear antibody test market size.
  • Ongoing R&D activities to enhance the testing technique and kits are key opportunities that can propel the market expansion in a long run.

Scope of the Report

The report on the global antinuclear antibody test market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Antinuclear Antibody Test Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Reagents & Assay Kits, Systems, and Software & Services), Techniques (ELISA, Immunofluorescence Assay, and Multiplex Assay), Applications (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s Syndrome, Scleroderma, and Others), and End-users (Hospitals, Clinical Laboratories, Physician Office Laboratories, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast

Key Players Covered in the Report

Thermo Fisher Scientific Inc.; Alere Inc.; Grifols Inc.; Bio-Rad Laboratories; Antibodies Inc.; Immuno Concepts; Zeus Scientific; Inova Diagnostics; Erba Diagnostics; Euroimmun AG; and Trinity Biotech PLC

 

Global Antibody Antinuclear Test Market Segment Insights

Reagents & assay kits segment to constitute a largest share
Based on products, the global antinuclear antibody test market is segmented into reagents & assay kits, systems, and software & services. The reagents & assay kits is expected to constitute a large market share during the period 2021-2028. Reagents and assay kits can easily impact the entire execution of an assay and also help in the creation of standardized workflows in order to help the researchers and scientists upon various fields. Standard reagents and assay kits play an integral part in the achieving efficient and accurate results besides offering other advantages such as improved efficiency, cost-effectiveness, and standardized results. Rising number of reagents and assay kits agreements are key factors pushing the segment growth.
 

Antinuclear Antibody Test Market By Products


Immunofluorescence assay to dominate the market
On the basis of techniques, the market is segmented into ELISA, immunofluorescence assay, and multiplex assay. The immunofluorescence assay is likely to dominate the global antinuclear antibody test market due to the high adoption of this assay diagnosis. Immunofluorescence assay is benchmarked for the gold standard of ANA testing owing to the superior sensitivity of this technique compared to other methods. It is able to identify various patterns that can indicate associated antibodies along with underlying disorders such as speckled, homogeneous, and others. On the other hand, the ELISA segment is anticipated to register a high CAGR during the forecast period 2021-2028 owing to its increasing adoption. ELISA is running mostly on automation, which do not require high skill level operators.

Rheumatoid arthritis segment to hold a major share
Based on applications, the global antinuclear antibody test market is divided into rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, Scleroderma, and others. The rheumatoid arthritis segment is projected to hold a major share in the market owing to the increasing occurrences of this disease. As per a data published by the US Centers of Disease Control and Prevention (CDC), approximately 54 million adults were suffering from arthritis that constituted nearly one fourth of Americans. The CDC further stated that by 2040, 78 million adults could have been facing arthritis and doctoral had to be diagnosed properly. Meanwhile, the systemic lupus erythematosus segment is a fast-growing segment due to the increasing awareness along with wide government initiatives and funding to improve the number of approvals for this test.

Hospitals segment to dominate the market
On the basis of end-users, the market is divided into hospitals, clinical laboratories, physician office laboratories, and others. The hospitals segment is projected to dominate the market share in the coming years owing to easy and safe access. Rising preference for patients visiting hospitals for the testing is due to the wide presence of medical staffs including doctors and technicians. This is expected to boost the segment growth. On the other hand, the physician office laboratories segment is anticipated to register a considerable CAGR during the forecast period due to the increased essential role of physician’s role in the present healthcare delivery system.

North America is projected to account for a key revenue market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to account for a key market share in terms of revenue during the forecast period, 2021-2028. The presence of key regional players in this region especially in the US is a major factor boosting the regional market growth. Moreover, existing advanced healthcare infrastructure and favorable insurance rules to its citizens as well as massive funding for research and development along with the early adoption of advanced technology in medicine are key factors fueling the regional market growth.

The market in Asia Pacific is, however, anticipated to expand at a high CAGR during the forecast period owing to rising awareness of the diseases and growing demand for tests in the region.
 

Antinuclear Antibody Test Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antinuclear Antibody Test Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Antinuclear Antibody Test Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Antinuclear Antibody Test Market - Supply Chain
  4.5. Global Antinuclear Antibody Test Market Forecast
     4.5.1. Antinuclear Antibody Test Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Antinuclear Antibody Test Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Antinuclear Antibody Test Market Absolute $ Opportunity
5. Global Antinuclear Antibody Test Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Antinuclear Antibody Test Market Size and Volume Forecast by Applications
     5.3.1. Rheumatoid Arthritis
     5.3.2. Systemic Lupus Erythematosus
     5.3.3. Sjogren’s Syndrome
     5.3.4. Scleroderma
     5.3.5. Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Antinuclear Antibody Test Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Antinuclear Antibody Test Market Size and Volume Forecast by End Users
     6.3.1. Hospitals
     6.3.2. Clinical Laboratories
     6.3.3. Physician Office Laboratories
     6.3.4. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Antinuclear Antibody Test Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Antinuclear Antibody Test Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Antinuclear Antibody Test Demand Share Forecast, 2019-2026
8. North America Antinuclear Antibody Test Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Antinuclear Antibody Test Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Antinuclear Antibody Test Market Size and Volume Forecast by Applications
     8.4.1. Rheumatoid Arthritis
     8.4.2. Systemic Lupus Erythematosus
     8.4.3. Sjogren’s Syndrome
     8.4.4. Scleroderma
     8.4.5. Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. North America Antinuclear Antibody Test Market Size and Volume Forecast by End Users
     8.7.1. Hospitals
     8.7.2. Clinical Laboratories
     8.7.3. Physician Office Laboratories
     8.7.4. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Antinuclear Antibody Test Demand Share Forecast, 2019-2026
9. Latin America Antinuclear Antibody Test Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Antinuclear Antibody Test Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Antinuclear Antibody Test Market Size and Volume Forecast by Applications
     9.4.1. Rheumatoid Arthritis
     9.4.2. Systemic Lupus Erythematosus
     9.4.3. Sjogren’s Syndrome
     9.4.4. Scleroderma
     9.4.5. Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Latin America Antinuclear Antibody Test Market Size and Volume Forecast by End Users
     9.7.1. Hospitals
     9.7.2. Clinical Laboratories
     9.7.3. Physician Office Laboratories
     9.7.4. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Antinuclear Antibody Test Demand Share Forecast, 2019-2026
10. Europe Antinuclear Antibody Test Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Antinuclear Antibody Test Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Antinuclear Antibody Test Market Size and Volume Forecast by Applications
     10.4.1. Rheumatoid Arthritis
     10.4.2. Systemic Lupus Erythematosus
     10.4.3. Sjogren’s Syndrome
     10.4.4. Scleroderma
     10.4.5. Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Europe Antinuclear Antibody Test Market Size and Volume Forecast by End Users
     10.7.1. Hospitals
     10.7.2. Clinical Laboratories
     10.7.3. Physician Office Laboratories
     10.7.4. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Antinuclear Antibody Test Demand Share Forecast, 2019-2026
11. Asia Pacific Antinuclear Antibody Test Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Antinuclear Antibody Test Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Antinuclear Antibody Test Market Size and Volume Forecast by Applications
     11.4.1. Rheumatoid Arthritis
     11.4.2. Systemic Lupus Erythematosus
     11.4.3. Sjogren’s Syndrome
     11.4.4. Scleroderma
     11.4.5. Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Asia Pacific Antinuclear Antibody Test Market Size and Volume Forecast by End Users
     11.7.1. Hospitals
     11.7.2. Clinical Laboratories
     11.7.3. Physician Office Laboratories
     11.7.4. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Antinuclear Antibody Test Demand Share Forecast, 2019-2026
12. Middle East & Africa Antinuclear Antibody Test Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Antinuclear Antibody Test Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Antinuclear Antibody Test Market Size and Volume Forecast by Applications
     12.4.1. Rheumatoid Arthritis
     12.4.2. Systemic Lupus Erythematosus
     12.4.3. Sjogren’s Syndrome
     12.4.4. Scleroderma
     12.4.5. Others
  12.5. Basis Point Share (BPS) Analysis by Applications
  12.6. Y-o-Y Growth Projections by Applications
  12.7. Middle East & Africa Antinuclear Antibody Test Market Size and Volume Forecast by End Users
     12.7.1. Hospitals
     12.7.2. Clinical Laboratories
     12.7.3. Physician Office Laboratories
     12.7.4. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Antinuclear Antibody Test Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Antinuclear Antibody Test Market: Market Share Analysis
  13.2. Antinuclear Antibody Test Distributors and Customers
  13.3. Antinuclear Antibody Test Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Thermo Fisher Scientific Inc.
     13.4.2. Alere Inc.
     13.4.3. Grifols Inc.
     13.4.4. Bio-Rad Laboratories
     13.4.5. Antibodies Inc.

Segments Covered in the Report
The global antinuclear antibody test market has been segmented in terms of

Products

  • Reagents & Assay Kits
  • Systems
  • Software & Services

Techniques

  • ELISA
  • Immunofluorescence Assay
  • Multiplex Assay

Applications

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Sjogren’s Syndrome
  • Scleroderma
  • Others

End-users

  • Hospitals
  • Clinical Laboratories
  • Physician Office Laboratories
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Thermo Fisher Scientific Inc.
  • Alere Inc.
  • Grifols Inc.
  • Bio-Rad Laboratories
  • Antibodies Inc.
  • Immuno Concepts
  • Zeus Scientific
  • Inova Diagnostics
  • Erba Diagnostics
  • Euroimmun AG
  • Trinity Biotech PLC

Some of the major players competing in the global antinuclear antibody test market size are Thermo Fisher Scientific Inc.; Alere Inc.; Grifols Inc.; Bio-Rad Laboratories; Antibodies Inc.; Immuno Concepts; Zeus Scientific; Inova Diagnostics; Erba Diagnostics; Euroimmun AG; and Trinity Biotech PLC. These players are actively focusing on the research and development activities to provide advanced ANA diagnostics to all the people around the globe with lower cost and increasing time efficiency. Grifols Inc., in 2018, have received the US Food and Drug Administration (FDA) approval to launch their new diagnostic treatment and examinations for lupus and other autoimmune disorders.
 

Antinuclear Antibody Test Market Key Players

Buy Report